Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) granted options covering 133,000 shares to seven newly hired employees on Sept. 1, using equity compensation to support hiring as …
Orchestra BioMed Grants 133,000 Options to New Hires Read More NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) will present its investment case to investors at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 16 as …
Orchestra BioMed Puts Pivotal Programs Before Investors Read More NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) will present its biomedical development strategy to investors at the Wells Fargo 21st Annual Healthcare Conference on Sept. 10 as …
Orchestra BioMed Sets Wells Fargo Investor Presentation Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) widened its second-quarter loss by 23% as spending increased on two pivotal cardiovascular trials, while $35 million of strategic capital …
Orchestra BioMed Loss Widens as Pivotal Trials Advance Read More NEW HOPE, PA — Orchestra BioMed Holdings (Nasdaq: OBIO) has been added to the Russell 3000 and Russell 2000 indexes, a move that could increase the company’s visibility among institutional …
Orchestra BioMed Added to Russell Indexes, Expanding Visibility Read More NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) has granted stock options covering 85,500 shares to five newly hired employees, using an inducement plan designed to support recruitment …
Orchestra BioMed Grants Equity Awards to New Employees Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) outlined a 2027 timeline for pivotal hypertension trial data and potential FDA submissions as the company and partner Medtronic advance …
Orchestra BioMed Advances FDA Path for Hypertension Device Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) said it expects to complete enrollment in its pivotal BACKBEAT clinical trial by the end of the third quarter of …
Orchestra BioMed Targets 2027 Data for Hypertension Trial Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) received a $15 million investment from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) tied to the company’s ongoing cardiovascular device trials, completing …
Orchestra BioMed Secures Ligand Funding for Pivotal Trials Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) received a $20 million investment from Medtronic plc (NYSE: MDT) tied to the companies’ ongoing collaboration to develop a pacemaker-based …
Orchestra BioMed Secures Medtronic Funding for Hypertension Trial Read More